

Technical Data Sheet

InVivoSIM anti-human PD-1 (Tislelizumab Biosimilar)



Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: SIM0038
Clone: Tislelizumab
Isotype: Human IgG4, κ
Recommended Isotype Control(s): RecombiMAb human IgG4 (S228P/R409K) isotype control, anti-hen egg lysozyme
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Mutations: S228P/E233P/F234V/L235A/D265A/R409K
Immunogen: Human PD-1
Reported Applications: Blocking of PD-1/PD-L signaling
Functional assays
ELISA
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤ 0.5 EU/mg (≤ 0.0005 EU/ μ g)
Determined by LAL gel clotting assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: 0.2 μ m filtration
Production: Purified from cell culture supernatant in an animal-free facility
Purification: Protein A
Aggregation: $< 5\%$
Determined by SEC
RRID:
Molecular Weight: 150 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tislelizumab making it ideal for research use. This Tislelizumab biosimilar reacts with human PD-1 (programmed death-1) also known as CD279. PD-1 is a 50-55 kDa cell surface receptor encoded by the Pdc1 gene that belongs to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. PD-1 expression declines after successful elimination of antigen. Additionally, Pdc1 mRNA is expressed in developing B

lymphocytes during the pro-B-cell stage. PD-1's structure includes a ITIM (immunoreceptor tyrosine-based inhibitory motif) suggesting that PD-1 negatively regulates TCR signals. PD-1 signals via binding its two ligands, PD-L1 and PD-L2 both members of the B7 family. Upon ligand binding, PD-1 signaling inhibits T-cell activation, leading to reduced proliferation, cytokine production, and T-cell death. Additionally, PD-1 is known to play key roles in peripheral tolerance and prevention of autoimmune disease. Induced PD-L1 expression is common in many tumors including squamous cell carcinoma, colon adenocarcinoma, and breast adenocarcinoma. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. PD-L1 overexpression results in increased resistance of tumor cells to CD8 T cell mediated lysis. In experimental models of melanoma, tumor growth can be transiently arrested via treatment with antibodies which block the interaction between PD-L1 and its receptor PD-1. The structure of Tislelizumab has been modified to maximally inhibit the binding of PD-1 to PD-L1 and minimize the binding of Tislelizumab to Fcγ receptors. The epitope of Tislelizumab is formed on the CC' loop of the front β sheet face of PD-1, which is innovative among anti-PD-1 antibodies; in comparison, other PD-1 antibodies, like Nivolumab and Pembrolizumab, bind to the N-terminal region and the C'D loop of PD-1, respectively. Tislelizumab is able to bind to human PD-1 with high specificity and affinity, with the disassociation constant being 0.15 nmol/L. At the 5 mg/kg dose, PD-1 receptor occupancy is >90%. In clinical studies, Tislelizumab has shown preliminary anti-tumor effects in various solid tumors.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit


https://bioxcell.com/sim0038?bxcs=9k1b3a#tab_references

or scan the QR code below.



Binding Validation

Validation data shown below confirms that this clone binds to its target antigen. For lot specific binding validation data, e-mail technicalservice@bioxcell.com.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for human use. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2025 Bio X Cell, LLC